New adjuvant renal cell carcinoma combo lowers recurrence risk

Clinical takeaway: In patients with resected clear-cell renal-cell carcinoma at increased risk for recurrence, adding belzutifan to adjuvant pembrolizumab improved disease-free survival but increased serious toxicity. The practical question is whether a lower recurrence risk justifies the added adverse-event burden, especially because overall survival was not significantly different at this interim analysis.

Adjuvant pembrolizumab is already an important post-nephrectomy option for patients with clear-cell renal-cell carcinoma at increased risk for recurrence. The LITESPARK-022 trial tested whether adding belzutifan, an oral hypoxia-inducible factor 2α inhibitor, could further reduce recurrence risk.

The phase 3 trial found that pembrolizumab plus belzutifan led to significantly higher disease-free survival than pembrolizumab plus placebo after nephrectomy. At 24 months, estimated disease-free survival was 80.7% with pembrolizumab-belzutifan and 73.7% with pembrolizumab alone.

That difference matters because recurrence after surgery remains a major concern in higher-risk clear-cell RCC, and adjuvant treatment decisions often involve balancing a chance of longer disease-free time against treatment toxicity, monitoring burden, and patient preference.

The overall survival data were not yet definitive. At the interim analysis, 24-month overall survival was similar between groups: 96.2% with pembrolizumab-belzutifan and 95.7% with pembrolizumab-placebo.

Toxicity is the key tradeoff. Grade 3 or higher adverse events occurred in 52.1% of patients receiving pembrolizumab-belzutifan and 30.2% of those receiving pembrolizumab alone. That higher adverse-event rate is clinically important in the adjuvant setting, where patients may be disease-free after surgery and treatment is intended to reduce future recurrence risk.

The findings suggest that adding belzutifan could become a more intensive adjuvant strategy for selected patients at high recurrence risk, but the benefit-risk discussion should be individualized. Patients with the highest concern for recurrence may value the disease-free survival gain more, while others may prioritize avoiding added toxicity when an overall survival advantage has not yet been shown.

“Treatment with pembrolizumab–belzutifan led to significantly higher disease-free survival, with a greater risk of grade 3 or higher toxic effects, than treatment with pembrolizumab monotherapy after nephrectomy in participants with clear-cell renal-cell carcinoma at increased risk for recurrence,” the study authors concluded.

Source: Choueiri TK, et al. (2026 July 1). N Engl J Med. Adjuvant pembrolizumab plus belzutifan for renal-cell carcinoma